DNA-binding proteins in the sera of patients with malignant melanoma
β Scribed by G. Reimer; M. Maibach; G. Leonhardi
- Publisher
- Springer-Verlag
- Year
- 1979
- Tongue
- English
- Weight
- 656 KB
- Volume
- 264
- Category
- Article
- ISSN
- 0340-3696
No coin nor oath required. For personal study only.
β¦ Synopsis
Zentrum der Dermatologie und Venerologie (Biochemie) der J. W. Goethe-Universit~it, Theodor-Stern-Kai 7, D-6000 Frankfurt a. M., Federal Republic of Germany Summary. Sera of patients with various malignancies are known to contain DNA-binding proteins (DBP) which are not present in sera of normal individuals. In this paper sera of patients with malignant melanoma (MM) were examined as to whether characteristic DBP are present, too.
DBP are isolated by DNA-affinity chromatography and represent 0 . 5 -0.9 % of all serum proteins. After separation of the DBP by SDS slab gel electrophoresis no typical DBP is detectable in sera of MM-patients. However, quantitative differences are found in sera of patients in the clinical stages I -III and/or tumor level 3 -5 :
-
All 9 sera of patients who had clinical signs of MM contain more DBP with molecular weight (row) of 20,000-24,000 dalton than control sera. However, these DBP are only increased in 30% of the 22 sera from MMpatients who had clinical signs for 1 3 -7 3 months after tumor excision.
-
All sera of the 10 MM-patients of whom sera were drawn twice after tumor excision at an interval of 7 -46 months without clinical signs, showed a reduction of DBP with mw 30,000, 68,000, and 165,000.
π SIMILAR VOLUMES
## Abstract Serum tyrosinase activity has been measured by adapting the [^3^]tyrosine assay for tyrosinase and significant elevations of serum tyrosinase activity were found in patients with malignant melanoma. In contrast to findings in a study which utilized [^14^C]tyrosine, augmented levels of t
Serum levels of sialyltransferase and sialic acid were measured in patients with malignant melanomas (n = 49), healthy control persons (n = 20), and patients with non-malignant skin disorders (n = 30). Both parameters were found to be higher in malignant melanoma patients than in healthy control per
## Abstract Sera frour 146 patients with malignancy, 59 normal controls and 42 patients hospitalized with nonβmalignant diseases were examined by a precipitin test with monoclonal rheumatoid factor (mRF) for the presence of circulating immune complexes containing IgG. Fortyβtwo (29%) of the sera fr